This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Momenta Pharmaceuticals' Management Presents At Deutsche Bank BioFEST 2011 - Event Transcript

Momenta Pharmaceuticals, Inc. (MNTA)

Deutsche Bank BioFEST

December 05, 2011 9:00 a.m. ET

Executives

Rick Shea - SVP and CFO

Ganesh Venkataraman - CSO, SVP, Research and Co-Founder

Analysts

Robyn Karnauskas - Deutsche Bank Securities

Presentation

Robyn Karnauskas - Deutsche Bank Securities

Thank you all for joining us and for those of you on the webcast. I am Robyn Karnauskas. And next, we have Momenta Pharmaceuticals. And it’s my pleasure to introduce, not only Rick Shea, the CFO, but also Ganesh Venkataraman – did I say that correctly – which is the one of the founders and chief scientific officer of Momenta.

And actually for those of you who are listening on the webcast, if you want to email me any questions, robyn.karnauskas@db.com. So with Ganesh here, he could answer any questions around their acquisition this morning and around some of the science behind Momenta.

And for those of you in the audience, again, we’re trying to use the DB app to sort of get some real-time feedback on the conference.

So with that, we’ll start off talking about – talking about Lovenox, first of all. You guys have been very successful with defending your patents. Maybe talk a little bit about -- you've got several cases actually ongoing. Maybe just give everyone in the audience an update on when is the next data point for each of those court cases? When we’re going to hear.

Rick Shea

So as you know we have been – in response to Amphastar’s approval for generic Lovenox on September 19, we sued Amphastar and Watson under our patents and obtained initially a temporary restraining order and then a temporary injunction against Amphastar and Watson, preventing them from launching.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,757.91 +138.40 0.79%
S&P 500 2,077.42 +14.31 0.69%
NASDAQ 5,013.1230 +26.2560 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs